A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD

BACKGROUND: The combination of the inhaled muscarinic antagonist umeclidinium (UMEC) with the long-acting β(2)-agonist vilanterol (VI) has been shown to provide significant improvements in lung function compared with UMEC, VI, or placebo (PBO) in patients with chronic obstructive pulmonary disease (...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Chron Obstruct Pulmon Dis
Autors principals: Siler, Thomas M, Donald, Alison C, O’Dell, Dianne, Church, Alison, Fahy, William A
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2016
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4869636/
https://ncbi.nlm.nih.gov/pubmed/27274218
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S102962
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars